JB Pharma charts a strategic shift towards chronic diseases and cardiology care
In an interview with CNBC-TV18, Nikhil Chopra, CEO and Whole-time Director of JB Pharma underlined the intention to concentrate on the chronic aspects of healthcare with a specific emphasis on lifestyle diseases, particularly in the field of cardiology.
JB Pharma, formerly known as JB Chemicals and Pharmaceuticals, is embarking on a strategic transition towards focusing more on the chronic segment of the pharmaceutical business, with a specific emphasis on lifestyle diseases, particularly in the field of cardiology.
In an interview with CNBC-TV18, Nikhil Chopra, CEO and Whole-time Director of the Mumbai-based company underlined the intention to concentrate on the chronic aspects of healthcare. The company's strategic vision centres around developing and offering innovative solutions for lifestyle diseases, with a primary focus on cardiology-related conditions.
Chopra stated that the pharmaceutical industry grew at 7% during the first half of the year and JB Pharma's growth was also in line with the industry average.
Also Read
JB Pharma's approach to business extends beyond acquisitions. The company has undertaken a holistic strategy that holds several key sides. Over the past three years, they have focused on building strong brand portfolios, nurturing existing business segments, and enhancing their contribution to the chronic disease category.
The company’s growth includes an acquisition valued at ₹300 crore, but its organic business in India is a significant contributor. With an estimated ₹2,000 crore in organic business, JB Pharma's homegrown segments account for approximately ₹1,500 crore of this total.
In the July-September quarter, the company reported a revenue growth of 9% year-on-year (YoY) at ₹881.7 crore, with a margin of 27.6% compared to 22.8%, and a profit increase of 33% at ₹147.3 crore, up from ₹111.08 crore.
On November 9, shares of the company gained over 5% to reach their 52-week high of ₹1,536.25 apiece on NSE. The shares have gained over 47% in the last six months. The company's market capitalisation was at ₹22,653.58 crore.
For more details, watch the accompanying video
(Edited by : Shweta Mungre)
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Supreme Court refuses plea seeking 6-year poll ban on PM
May 14, 2024 7:14 PM
Punjab Lok Sabha elections 2024: A look at BJP candidates
May 14, 2024 7:06 PM
Lok Sabha polls: EC disposes of 90% complaints related to MCC violations
May 14, 2024 4:45 PM
Jharkhand Lok Sabha elections 2024: All about INDIA bloc candidates
May 14, 2024 2:52 PM